

# Francois Lemonnier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/576991/publications.pdf>

Version: 2024-02-01

17  
papers

1,762  
citations

759233

12  
h-index

888059

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

2268  
citing authors

#	ARTICLE	IF	CITATIONS
1	IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2012, 119, 1901-1903.	1.4	435
2	Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. <i>Blood</i> , 2012, 120, 1466-1469.	1.4	402
3	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. <i>Blood</i> , 2016, 128, 1490-1502.	1.4	255
4	Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. <i>Haematologica</i> , 2017, 102, e148-e151.	3.5	163
5	Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2018, 132, 2305-2309.	1.4	124
6	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 15084-15089.	7.1	96
7	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 923-930.	4.1	79
8	The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 mutations. <i>Modern Pathology</i> , 2019, 32, 1123-1134.	5.5	54
9	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 539-548.	5.2	38
10	Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 864-868.	1.7	33
11	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. <i>Blood</i> , 2021, 137, 3495-3506.	1.4	22
12	Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. <i>Blood Advances</i> , 2020, 4, 3217-3223.	5.2	16
13	Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations. <i>Modern Pathology</i> , 2022, 35, 1126-1136.	5.5	16
14	History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis. <i>ESC Heart Failure</i> , 2021, 8, 5501-5512.	3.1	11
15	Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment. <i>Current Opinion in Oncology</i> , 2021, 33, 400-405.	2.4	7
16	Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality. <i>Cancers</i> , 2022, 14, 2392.	3.7	7
17	Prevalence and determinants of iron deficiency in cardiac amyloidosis. <i>ESC Heart Failure</i> , 2022, 9, 1314-1327.	3.1	4